Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
Evaluation of Cell-Penetrating Peptide Delivery of Antisense Oligonucleotides for Therapeutic Efficacy in Spinal Muscular Atrophy.
Methods Mol Biol. 2019;2036:221-236
Authors: Hammond SM, Abendroth F, Gait MJ, Wood MJA
Abstract
Antisense oligonucleotides (ASOs) are a widely used form of gene therapy, which is translatable to multiple disorders. A major obstacle for ASO efficacy is its bioavailability for in vivo and in vitro studies. To overcome this challenge we use cell-penetrating peptides (CPPs) for systemic delivery of ASOs. One of the most advanced clinical uses of ASOs is for the treatment of spinal muscular atrophy (SMA). In this chapter, we describe the techniques used for in vitro screening and analysing in vivo biodistribution of CPP-conjugated ASOs targeting the survival motor neuron 2, SMN2, the dose-dependent modifying gene for SMA.
PMID: 31410800 [PubMed - in process]
Source: Mol Biol Cell - Category: Molecular Biology Authors: Hammond SM, Abendroth F, Gait MJ, Wood MJA Tags: Methods Mol Biol Source Type: research
More News: Brain | Gene Therapy | Genetics | Molecular Biology | Motor Neurone Disease | Neurology | Spinal Muscular Atrophy | Study